GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » NonCurrent Deferred Liabilities

Relmada Therapeutics (STU:4E2) NonCurrent Deferred Liabilities : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Relmada Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2025 was €0.00 Mil.

Relmada Therapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Relmada Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics NonCurrent Deferred Liabilities Chart

Relmada Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines